Galapagos NV: business update: http://t.co/6w1jppWE
posted 6 days ago
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
VIB researcher Diether Lambrechts, associated with KU Leuven, has discovered a biomarker that might potentially predict which patients will benefit more from treatment with bevacizumab (Avastin). If validated, this discovery could be an important step towards personalized medicine and patient-tailored use of this important cancer drug. read more
Dystonia is the third most common movement disorder after Parkinson's and essential tremor. In spite of this, almost no dystonia research is taking place in Belgium, whether clinical or basic. Rose Goodchild wants to change that. The British-American researcher is joining the VIB Center for the Biology of Disease, headed by Bart De Strooper, at KU Leuven. On May 11, 2012, Goodchild is giving an inaugural lecture to unveil her research plans for the next five years. read more
Neuroscientist Patrik Verstreken, associated with VIB and KU Leuven, succeeded in undoing the effect of one of the genetic defects that leads to Parkinson's using vitamin K2. His discovery gives hope to Parkinson's patients. This research was done in collaboration with colleagues from Northern Illinois University (US) and will be published this evening on the website of the authorative journal Science. read more
Amakem NV, a kinase platform company focusing on ophthalmology, presented key preclinical data on its potent, locally active Rho Kinase (ROCK) inhibitor AMA0076 at the 2012 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held at Fort Lauderdale, US from 6 – 10 May. The ARVO meeting is the world’s largest gathering of international eye and vision researchers. read more
Today Multiplicom, ICAN and ICM announced they signed an agreement to jointly develop a new generation of molecular diagnostic tests to identify disease predisposition mutations in cardiovascular, metabolic and neurological diseases. Multiplicom’s expertise in the development of massive parallel sequencing based molecular diagnostics in combination with the disease specific knowledge and the availability of well documented samples at ICAN and ICM will lead to the development of innovative diagnostic tests that will help patients and their doctors to prevent and/or cure disease in an early stage. read more
Complix NV, a biopharmaceutical company focused on the discovery and development of Alphabodies, a unique class of protein therapeutics that are active against both extracellular and intracellular disease targets, announces that it will provide an update on new developments with its Alphabody™ platform at the Biologics Partnering Forum in Boston, MA on 29 April 2012. read more
